Tandem Diabetes Care Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
All right. Good morning, and welcome. This is Marissa Bych from Morgan Stanley Equity Research. I work with David Lewis in Medical Devices. I'm very excited this morning to have John Sheridan, the CEO; and Leigh Vosseller, the CFO of Tandem Diabetes with me this morning. And Leigh and John, I hosted you both last year in-person, more fortunately, but we have the opportunity to talk a little bit about the Basal-IQ success that you had, had. And obviously, now we get to talk more about Control-IQ's success.
So let's maybe start off with some of the nearer-term dynamics and then work into product specifics and what you have in the pipeline catalysts ahead. But it's great to have you both here.
Questions & Answers
The first thing I want to talk about is just that there were a lot of moving factors in your recent results, right? So Control-IQ momentum most clearly. And COVID-19, obviously,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
